

## INTERIM FORMULARY UPDATE

The following recommendations, made at the April 29, 2005 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
tegaserod	Zelnorm®	Tablet: 2 mg, 6 mg	Gastrointestinal
pioglitazone	Actos®	Tablet: 15 mg, 30 mg, 45 mg	Diabetic/antidiabetic
montelukast	Singulair®	Tablet: 10 mg Tablet, chewable: 4 mg	Respiratory

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on the Sectional Reviews for Muscle Relaxant, Antiparkinson, Migraine, Miscellaneous CNS, and Endocrine Agents:

cyclobenzaprine	Flexeril®	Tablet: 5 mg, 10 mg	Muscle Relaxant
entacapone	Comtan®	Tablet: 200 mg	Antiparkinson
pergolide	Permax®	Tablet: 0.05 mg, 0.25 mg, 1 mg	Antiparkinson
pramipexole	Mirapex®	Tablet: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 1.5 mg	Antiparkinson
risedronate	Actonel®	Tablet: 5 mg, 30 mg, 35 mg	Endocrine

Dosage strength/formulations **recommended to be deleted** from the DADS/DSHS Drug Formulary based on the Sectional Reviews for Muscle Relaxant, Antiparkinson, Migraine, Miscellaneous CNS, and Endocrine Agents:

Generic Name	Brand Name	Dosage Form	Dosage Forms Still Available
biperiden	Akineton®	Injection: 5 mg/ml	Tablet: 2 mg
levodopa	Larodopa®	Capsule: 100 mg, 250 mg, 500 mg Tablet: 100 mg, 250 mg, 500 mg	None
Trihexyphenidyl	Artane®	Capsule, sustained release: 5 mg	Elixir: 2 mg/5 ml Tablet: 2 mg, 5 mg
propranolol	Inderal®	Tablet: 90 mg	Capsule, sustained release: 60 mg, 80 mg, 120 mg, 160 mg Injection: 1 mg/ml Solution, oral: 4 mg/ml, 8 mg/ml, 80 mg/ml Tablet: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg

Generic Name	Brand Name	Dosage Form	Dosage Forms Still Available
Corticotropin	ACTH®	Injection, repository: 40 units/ml, 80 units/ml Powder for injection: 25 units, 40 units	None
Cortisone		Injection: 50 mg/ml Tablet: 5 mg, 10 mg, 25 mg	None
Liotrix	Thyrolar® Euthroid®	Tablet: 15 mg, 30 mg, 60 mg, 120 mg, 180 mg (thyroid equivalent)	None
Methyltestosterone	Android® Oreton®	Capsule: 10 mg Tablet: 10 mg, 25 mg Tablet, buccal: 5 mg, 10 mg	None
Prednisolone	Delta-Cortef®	Injection, as sodium phosphate: 20 mg/ml Liquid, oral: 5 mg/ml	Syrup: 15 mg/5 ml Tablet: 5 mg
Prednisone	Meticorten® Deltasone®	Solution, oral, concentrate: 5 mg/ml with 30% alcohol	Syrup: 5 mg/5 ml Tablet: 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg
Probenecid	Benemid®	Tablet: 500 mg	None
Testosterone	Androlin®	Injection, in oil, as enanthate: 100 mg/m, 200 mg/ml	Injection, in oil, as cypionate: 100 mg/m, 200 mg/ml

Dosage strength(s) **recommended to be added** to the DADS/DSHS Drug Formulary based on the Agents for Migraine Sectional Review:

Generic Name	Brand Name	Dosage Form	Classification
metoprolol	Lopressor®	Tablet: 25 mg	Migraine
alendronate	Fosamax®	Oral solution: 70 mg/ 75 ml	Endocrine
estradiol	Vagifem®	Vaginal Tablet: 25 mcg	Endocrine

**Other recommendations:**

- Addition of timolol (Blocadren®) and fluoxetine (Prozac®) to the Migraine Section.
- The Miscellaneous CNS Section name will be changed to Dementia Agents.
- Addition of Depo-Medrol® as a trade name for methylprednisolone.
- Addition of Levoxyl® as a trade name for levothyroxine.

Previously, the Executive Formulary Committee requested input from the field regarding the following drugs proposed for deletion from the DADS/DSHS Drug Formulary. Based on the field's response, the following drugs are deleted from the Drug Formulary.


Products **deleted** from the DADS/DSHS Drug Formulary based on these previous Sectional Reviews:  
**Analgesic Agents, Antiemetic/Antivertigo Agents, Sedative/Hypnotic Agents, Anticonvulsant Agents**

Generic Name	Brand Name	Dosage Forms To Be Deleted	Dosage Forms Still Available
Acetaminophen	Tylenol®	Liquid: 500 mg/15 ml Tablet: 650 mg	Liquid: 160 mg/5 ml Suppository, rectal: 120 mg, 125 mg, 325 mg, 650 mg Tablet: 325 mg, 500 mg Tablet, chewable: 80 mg
Aspirin		Tablet: 81 mg, 500 mg Tablet, enteric coated: 975 mg	Suppository, rectal: 300 mg, 600 mg Tablet: 325 mg Tablet, buffered: 325 mg with buffering agents Tablet, chewable: 81 mg Tablet, enteric coated: 81 mg, 325 mg, 500 mg, 650 mg
Ibuprofen	Motrin®	Tablet, chewable: 50 mg, 100 mg	Suspension, oral: 40 mg/ml, 100 mg/5 ml Tablet: 200 mg, 400 mg, 600 mg, 800 mg
Meclizine	Antivert®, Bonine®	Tablet, chewable: 25 mg	Tablet: 12.5 mg, 25 mg, 50 mg
Prochlorperazine	Compazine®	Suppository, rectal: 2.5 mg, 5 mg Syrup: 5 mg/5 ml	Injection: 5 mg/ml Suppository, rectal: 25 mg Tablet: 5 mg, 10 mg, 25 mg
Promethazine	Phenergan®	Syrup: 25 mg/5 ml	Injection: 25 mg/ml, 50 mg/ml Suppository, rectal: 12.5 mg, 25 mg, 50 mg Syrup: 6.25 mg/5 ml Tablet: 12.5 mg, 25 mg, 50 mg
Trimethobenzamide	Tigan®	Suppository, rectal: 100 mg	Capsule: 250 mg, 300 mg Injection: 100 mg/ml Suppository, rectal: 200 mg
Chloral hydrate	Noctec®	Suppository, rectal: 324 mg, 500 mg Syrup: 250 mg/5 ml	Capsule: 500 mg Syrup: 500 mg/5 ml
Clorazepate	Tranxene®, Tranxene SD®	Capsule: 3.75 mg, 7.5 mg, 15 mg	Tablet: 3.75 mg, 7.5 mg, 15 mg Tablet, sustained release: 11.25 mg, 22.5 mg
Phenobarbital	Luminal®	Capsule: 16 mg Injection: 30 mg/ml, 60 mg/ml	Elixir: 20 mg/5 ml Injection: 65 mg/ml, 130 mg/ml Tablet: 8 mg, 15 mg, 16 mg, 30 mg, 32 mg, 60 mg, 65 mg, 100 mg

Other **recommendation(s)/addition(s)/revisions(s)** to the DADS/DSHS Drug Formulary:

- The brand name of galantamine is changing from Reminyl® to Razadyne™ in order to prevent confusion with Amaryl®

Approved:

  
\_\_\_\_\_  
Steven P. Shon, M.D.  
Medical Director

July 12, 2005  
\_\_\_\_\_  
Date: